Sirukumab
Sirukumab is a monoclonal antibody designed for the treatment of rheumatoid arthritis. It was developed by Janssen Biotech, a pharmaceutical company that is a division of Johnson & Johnson. Sirukumab works by targeting the interleukin-6 (IL-6) cytokine, which plays a key role in the inflammatory process of rheumatoid arthritis.
Development and Clinical Trials
The development of Sirukumab began in the early 2000s, with the aim of finding a more effective treatment for rheumatoid arthritis. The drug was designed to bind to the IL-6 cytokine, thereby inhibiting its function and reducing inflammation.
In 2017, the Food and Drug Administration (FDA) rejected the application for Sirukumab, citing concerns about safety and efficacy. The FDA requested additional data to further evaluate the safety and benefit-risk profile of the drug.
Mechanism of Action
Sirukumab is a monoclonal antibody that binds to the IL-6 cytokine. IL-6 is a protein produced by various cells in the body, including immune cells, and is involved in the inflammatory response. By binding to IL-6, Sirukumab prevents it from interacting with its receptor, thereby inhibiting the inflammatory response that contributes to the symptoms of rheumatoid arthritis.
Potential Side Effects
As with all medications, Sirukumab has the potential to cause side effects. These can include infections, neutropenia (a decrease in the number of white blood cells), and abnormalities in liver function tests. It is important for patients to discuss these potential risks with their healthcare provider before starting treatment with Sirukumab.
Future Research
Despite the initial rejection by the FDA, research into Sirukumab continues. Scientists are hopeful that with further study, they can address the FDA's concerns and eventually bring this promising treatment to patients with rheumatoid arthritis.
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD